Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer

Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT04215731 by Yanhong Deng, with a registry enrolment figure of 582 participants, started 2020-03-27 and due to reach its primary completion in 2026-09-01. Interventions recorded: Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab; Restaging; Concomitant Chemoradiotherapy; Surgery; Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging); Induction chemotherpay with FOLFOX. Conditions listed: Rectal Cancer. Primary outcome: Disease-free survival. Colorectal eligibility wording from the registry: "Histological or cytological documentation of adenocarcinoma of the rectal (\<12 cm from the anal verge)". Sites: China. No results are recorded here; the registry entry is the source.